# Pizarra — PT-pseudo_17f110c9e142 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_17f110c9e142
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.171 ng/mL²
  - PSA velocity: 0.72 ng/mL/yr
  - Prior PSA: 5.3 ng/mL
  - Prostate volume: 40.33 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8314881 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 40 mL. DRE nodus. csPCa 0.83.

Vitals: weight 70 kg, height 177 cm, BMI 22.3, BP 124/70 mmHg, HR 82 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2023).

Chief complaint: Specialist reassessment is requested due to a previous prostate cancer diagnosis coupled with a recent PSA increase to 6.9 ng/mL.

History: A 67-year-old retired warehouse worker initiated evaluation for prostate anomalies in 2024 after an initial PSA spike. Currently married yet residing independently, he relies on his adult son for emergency contact and his daughter for managing correspondence. Moderate lower urinary tract symptoms, notably nocturia and a diminished stream, yield an IPSS score of 17. Daily habits encompass a 20-minute walking routine and moderate alcohol intake averaging 16 units weekly. Recent outpatient screenings for hearing and actinic keratosis remain stable. He explicitly denies unexplained weight loss, skeletal pain, or haematuria, maintaining full independence in daily activities. Status: Ex-smoker (10 pack-yr, quit 2023).

Physical examination: Per rectum: Nodus DRE identifies a discrete, firm mass situated in the right peripheral zone, aligning with a cT2 classification. The remainder of the gland demonstrates symmetrical enlargement without additional abnormalities. Systemic assessment shows normal cardiorespiratory parameters. The individual maintains a well-nourished appearance and demonstrates unassisted mobility.

Patient info: retired warehouse worker; Married; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 16 units / week; exercise Walking 20 min/day; IPSS score: 17/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.42 +/- 0.20   (95% CI 0.08-0.82)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=6.9, age=67.0, psad=0.171, dre_ord=1.0, vol=40.33, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5.0, PSA=6.9, PSA density=0.171, DRE=Nodus, prior biopsy=Positive) and failed to incorporate the crucial context of the retrieved documents, such as the full mpMRI report, PSA trajectory, or laboratory panel.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.42 +/- 0.20). This wide interval suggests the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. Furthermore, the protocol expert noted that the decision is undetermined by the visible panel alone, meaning the prior's suggestion is based on insufficient evidence. The prior cannot account for the specific guideline constraints related to the prior positive biopsy status.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

Retrieving the radiology report would clarify if the PI-RADS 5 lesion has changed, which is critical for determining if a repeat biopsy is warranted.

GUIDELINE ANCHOR
The guideline search indicates that the decision is risk-adapted based on PI-RADS score and PSA density categories, noting that the detection rates for clinically significant prostate cancer vary significantly across these risk groups.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Prostate multiparametric MRI | Date: 03 Feb 2025 | Institution: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)
PI-RADS 5 lesion in the right peripheral zone. Lesion size is approximately 15 x 12 x 10 mm. No explicit comparison to a previous MRI is detailed in the impression, but the indication was a reassessment following a prior positive biopsy.

get_psa_trend
PSA trend shows a significant rise: 0.7 ng/mL at Oct 2022, 1.8 ng/mL at Dec 2023, and 6.9 ng/mL at Feb 2025.

get_previous_notes
29 Jun 2024: Initial workup commenced after a PSA of 5.3 ng/mL led to a biopsy confirming Gleason 3+4 malignancy. Patient is on active surveillance protocol.

get_lab_results
PSA: 6.9 ng/mL (03 Feb 2025). %Free PSA: 17% (03 Feb 2025).

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which could potentially influence the risk stratification, although the protocol expert stated it is not part of the biopsy work-up.

WHAT THE EVIDENCE SUPPORTS
Findings that argue FOR sampling this patient now:
- PI-RADS 5 lesion in the right peripheral zone.
- PSA velocity is high (from trend data).
- Patient is on an active surveillance protocol and a re-evaluation is requested.

Findings that argue AGAINST sampling this patient now:
- Prior biopsy confirmed Gleason 3+4 malignancy.
- Prostate volume is 40.33 mL.

WHERE THIS LEANS
The evidence strongly suggests a need for further tissue characterization due to the high-risk MRI finding (PI-RADS 5) and the rising PSA trajectory, despite the prior positive biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the retrieved evidence strongly suggests a need for further tissue characterization due to the high-risk PI-RADS 5 lesion and the significant PSA velocity of 0.72 ng/mL/yr. The decision to proceed is driven by the PI-RADS 5 finding and the rising PSA trajectory, which are factors that would inform definitive treatment planning. The statistical prior suggested no biopsy, but the retrieved documents indicate that the lack of a documented prior grade or comparison against a previous MRI means the biopsy is necessary to establish the current pathological status.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
